Wen Chen currently serves as the Head of CMC at ECCOGENE 诚益生物 since April 2022. Prior to this role, Wen Chen held the position of Senior Director of Pharmaceutical Sciences, Formulation Development at Karyopharm Therapeutics from 2013 to 2022, achieving the successful commercialization of Xpovio (Selinexor) with NDA approval in July 2019. Previous experience includes Director roles in various pharmaceutical companies, focusing on formulation technology, pharmaceutical services, and R&D management. Wen Chen's educational background includes a Ph.D. in Biopharmaceutical Science from Northeastern University and a degree from Guangzhou Medical College.
This person is not in the org chart
This person is not in any teams
This person is not in any offices